How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

167 results for

HIV related Myelopathy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Management of Chronic Pain in Survivors of Adult Cancers Full Text available with Trip Pro

peripheral neuropathy Raynaud’s syndrome Hormonal therapy–related pain syndromes Arthralgias Dyspareunia Gynecomastia Myalgias Osteoporotic compression fractures Radiation-related pain syndromes Chest wall syndrome Cystitis Enteritis and proctitis Fistula formation Lymphedema Myelopathy Osteoporosis Osteoradionecrosis and fractures Painful secondary malignancies Peripheral mononeuropathies Plexopathies: brachial, sacral Stem-cell transplantation–mediated graft-versus-host disease Arthralgias/myalgias (...) should be assessed. Clinicians should clearly understand terminology such as tolerance, dependence, abuse, and addiction as it relates to the use of opioids and should incorporate universal precautions to minimize abuse, addiction, and adverse consequences. Additional information is available at and . INTRODUCTION Section: As a result of extraordinary advancements in diagnosis and treatment, approximately 14 million individuals with a history of cancer (excluding nonmelanomatous skin cancers

2016 American Society of Clinical Oncology Guidelines

42. Acute Pain Management: Scientific Evidence

and the development of chronic pain ( Reardon 2015). The transition of acute postoperative or post-traumatic pain to pathological chronic pain is a complex and poorly understood process (Shipton 2014a). Biological, psychological, and social- environmental factors and the known polymorphisms in human genes are all involved in perpetuating the pain ( Walsh 2011). Anaesthetists and other physicians treating acute trauma play a pivotal role in the identification of factors that may lead to suboptimal pain control (...) was the “Declaration of Montreal”, which called for “access to pain management as a fundamental human right” (Cousins 2011). This included the management of acute pain. This fourth edition sums up the evidence currently available to assist health professionals in the management of acute pain. Additional literature has been reviewed from August 2009 to August 2014. Levels of evidence have been documented according to the National Health and Medical Research Council (NHMRC) designation ( NHMRC 1999). The Jadad

2015 Clinical Practice Guidelines Portal

43. Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)

Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect) Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect) (CSM-Protect) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01257828 Recruitment Status : Completed First Posted : December 10, 2010 Last Update Posted : November 2, 2018 Sponsor

2010 Clinical Trials

44. Teriflunomide

in the United States 14 2.4 Important Safety Issues with Consideration to Related Drugs 14 2.5 Summary of Presubmission Regulatory Activity Related to Submission 16 2.5.1 May 28, 2004 Clinical Hold of IND 16 2.5.2 November 12, 2004 End of Phase 2 meeting (EoP2) 17 2.5.3 August 2, 2005 Teleconference 18 2.5.4 June 27, 2006 Full Clinical Hold of IND 19 2.5.5 June 5, 2007 Response to sponsor’s questions in lieu of meeting 21 2.5.6 September 28, 2007 Correspondence regarding HIV issue 21 2.5.7 September 1, 2010 (...) a documented increase in LFTs (ALT 10 X ULN, AST 6.4 X ULN, Bili 1.2 X ULN) on Day 141 of treatment with 7 mg/day. Drug was discontinued on Day 143, and she underwent a washout procedure with cholestyramine from Day 147-157. Her LFTs increased to ALT 23 X ULN, AST 12.3 X ULN, and GGT 5.5 x ULN on Day 160. She was also reportedly icteric. She recovered on Day 189; viral serologies were negative. The increased incidence of Blood disorders was primarily related to mild neutropenia (with or without lymphopenia

2012 FDA - Drug Approval Package

45. Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714

vitamin B12 deficiency) History or known presence of infectious causes of myelopathy (e.g., syphilis, Lyme disease, human T-lymphotropic virus 1 (HTLV-1), herpes zoster myelopathy) History of genetically inherited progressive CNS degenerative disorder (e.g., hereditary paraparesis; MELAS [mitochondrial myopathy, encephalopathy, lactic acidosis, stroke] syndrome) Neuromyelitis optica History or known presence of systemic autoimmune disorders potentially causing progressive neurologic disease (e.g (...) immunodeficiency 4. Lack of peripheral venous access 5. Significant, uncontrolled disease, such as cardiovascular (including cardiac arrhythmia), pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine or gastrointestinal or any other significant disease that may preclude patient from participating in the study 6. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies 7. Congestive heart failure (New York Heart Association [NYHA] III or IV

2018 Clinical Trials

46. Tinnitus

from within or outside the head. Tinnitus most often occurs in the setting of concomitant sensorineural hearing loss (SNHL), particularly among patients with bother- some tinnitus and no obvious ear pathology. The quality of tinnitus can also vary, with ringing, buzzing, clicking, pulsa- tions, and other noises described by tinnitus patients. In addi- tion, the effects of tinnitus on health-related quality of life (QOL) vary widely, with most patients less severely affected but some experiencing (...) for thorough clinical evaluation to identify these poten- tially treatable and sometimes serious disorders. Clinicians should decide whether to apply these recommendations to patients with these conditions on an individualized basis. The guideline also excludes patients with pulsatile tinnitus, or tin- nitus related to complex auditory hallucinations or hallucina- tions related to psychosis or epilepsy. This is the first evidence-based clinical guideline developed for the evaluation and treatment

2014 American Academy of Otolaryngology - Head and Neck Surgery

47. An Update of Comprehensive Evidence-Based Guidelines for Interventional Techniques in Chronic Spinal Pain - Part 2 - Guidance and Recommendations

TECHNIQUES V. MANAGEMENT OF LOW BACK PAIN 1.0 Disc-Related Pathology, Spinal Stenosis, And Radiculitis 1.1 Diagnosis Of Disc-Related Lumbar Pathology 1.1.1 Diagnostic Interventional Techniques 1.2 Therapeutic Interventions Of Lumbar Discogenic Pathology 1.2.1 Epidural Injections 1.2.2 Lumbar Epidural Adhesiolysis 1.2.3 Thermal Annular Procedures 1.2.4 Percutaneous Disc Decompression 2.0 Lumbar Facet Joint Pain 2.1 Diagnosis of Lumbar Facet Joint Pain 2.1.1 Diagnostic Lumbar Facet Joint Blocks 2.2 (...) Therapeutic Lumbar Facet Joint Interventions 2.2.1 Radiofrequency Neurotomy 2.2.2 Therapeutic Facet Joint Nerve Blocks 2.2.3 Intraarticular Injections 3.1.1 Diagnostic Sacroiliac Joint Blocks 3.2 Therapeutic Sacroiliac Joint Interventions 3.2.1 Intraarticular Injections 3.2.2 Periarticular Injections 3.2.3 Conventional Radiofreqency Neurotomy 3.2.4 Cooled Radiofrequency Neurotomy 3.2.5 Pulsed Radiofrequency Neurotomy VI. MANAGEMENT OF NECK PAIN 1.0 Disc-Related Pathology, Spondylosis, Spinal Stenosis

2013 American Society of Interventional Pain Physicians

48. Investigation and Management of Antiphospholipid Syndrome

, M.G. ( 1993 ) The lupus anticoagulant. High incidence of ‘negative’ mixing studies in a human immunodeficiency virus‐positive population . Archives of Pathology and Laboratory Medicine , 117 , 595 – 601 . Cowchock, S. & Reece, E.A. ( 1997 ) Do low‐risk pregnant women with antiphospholipid antibodies need to be treated? Organizang Group of the Antiphospholipid Antibody Treatment Trial . American Journal of Obstetrics and Gynecology , 176 , 1099 – 1100 . Crowther, M.A. , Ginsberg, J.S. , Julian, J (...) . The guidance is updated with reference to relevant publications since 2000. Publications known to the writing group were supplemented with additional papers identified by searching PubMed for publications in the last 11 years using the key words: lupus anticoagulant, anticardiolipin, antiphospholipid, β2–glycoprotein I, antiprothrombin and limits (clinical trial, randomized control trial, meta‐analysis, humans, core clinical journals, English language). The writing group produced the draft guideline, which

2012 British Committee for Standards in Haematology

49. Family Practice Notebook Updates 2018

(hemeonc, pharm) May be used for vascular prevention (CAD or PAD) by adding 2.5 mg twice daily added to 81 mg in stable chronic CAD or PAD However, NNT 71 for serious CAD related event, NNT 147 for PAD related amputation and the NNH 80 to cause one major bleeding event (id, immunize, virus) As of 2018, is approved for use in 27-45 year old women and men at risk (rheum, cv) Avoid s and consider vasodilators (e.g. , , or in refractory cases, ) (er, pharm, toxin) Expect to see it in toothpaste, mouthwash (...) , , ) including joint aspiration Empiric initial management with and (psych, cd) Consider 0.2 mg/kg/hour in refractory (id, immunize) In the U.S., Human is rare (31 cases 2003-2016), and bats are the most common exposures Worldwide, is responsible for 59,000 human deaths per year, and dogs are a common source (ortho, sx, hand) Consider view if concern for or hook of hamate , or tubercle Consider clenched fist view to evaluate for Consider radial head-capitellum view to evaluate for High Flow Nasal Oxygen

2019 FP Notebook

50. PEMF as Adjunctive Treatment Following Surgical Repair of Full Thickness Rotator Cuff Tears

Official Title: Prospective, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Pulsed Electromagnetic Field (PEMF) Therapy as an Adjunctive Treatment to Surgical Repair of Full Thickness Rotator Cuff Tears Actual Study Start Date : January 15, 2018 Estimated Primary Completion Date : December 31, 2021 Estimated Study Completion Date : December 1, 2022 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm (...) imperfecta (OI) or Ehlers-Danlos syndrome (EDS). Subject has a known inflammatory or autoimmune connective tissue disease such as, but not limited to, gout affecting the shoulder, scleroderma, SLE, rheumatoid disease, or calcific tendonitis of the shoulder. Subject has a metabolic bone disease such as Paget's disease or osteomalacia. Subject has a deltoid defect, deltoid palsy or any other pseudoparalysis. Subject has HIV, hepatitis, or has had an active malignancy in the past 5 years. Subject has had

2017 Clinical Trials

51. Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector

(other than Bowen disease or cervical cancer); or has family history of cancer. Myelopathy, tumor-related cytogenetic changes or other more severe blood diseases. Has alcoholism experience within 6 months prior to enrollment. History of epilepsy. History of bone marrow transplantation. Existence of an available HLA-identical related donor. Pregnant or lactating females. Subject infected with HCV (HCV antibody positive), HBV (HBsAg positive), HIV (HIV antibody positive), HTLV (HTLV antibody positive (...) or disease Intervention/treatment Phase Beta-Thalassemia Genetic: Gene-modified autologous stem cells Not Applicable Detailed Description: Thalassemia is considered the most common genetic disorder worldwide. Beta-thalassemia is caused by mutations in the beta-globin gene which encodes the beta-globin protein, leading to the ineffective erythropoiesis, hemolysis and anemia. Currently, the only cure for thalassemia is bone marrow transplantation from a related, compatible donor, which has, however

2017 Clinical Trials

52. Central Pain Study for ABX-1431

as an isolated condition or with MS are excluded. Patients with a history of encephalitis are excluded. Patients with systemic inflammatory autoimmune disorders associated with TM are excluded (e.g. sarcoidosis, systemic lupus erythematosus, Sjogren's syndrome, Behcet's Syndrome, rheumatoid arthritis). TM secondary to infection of the nervous system is excluded (e.g. herpes virus, Lyme disease). TM associated with HIV infection is excluded. Patient has an onset of an MS, LETM or TM relapse or NMOSD acute (...) : Randomized Intervention Model: Crossover Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of ABX-1431 in Patients With Central Pain Actual Study Start Date : August 1, 2017 Actual Primary Completion Date : July 23, 2018 Actual Study Completion Date : July 24, 2018 Resource links provided by the National Library of Medicine related topics: resources

2017 Clinical Trials

53. The Confounding Burden of Psychological Impairments in Cervical Spine Surgery

classification: C2-C7 SVA > 8cm, Horizontal Gaze < -10 or > 25, T1S-CL > 20, myelopathy (JOA score <10) or severe adult spinal deformity based on SRS-Schwab classification (PI-LL > 20, PT >30, SVA > 90 mm) Undergoing simultaneous treatment for thoracolumbar spine related diagnoses at the time of enrollment History of any spinal surgery within the last 6 months Patients with neck pain attributable to trauma, idiopathic deformity, neoplasm, osteoporosis, or other medical condition. Unlikely to comply (...) : Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: The Confounding Burden of Psychological Impairments in Cervical Spine Surgery Actual Study Start Date : June 5, 2017 Estimated Primary Completion Date : April 3, 2019 Estimated Study Completion Date : April 3, 2019 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Comparison Group Patients with a zero risk score

2017 Clinical Trials

54. Panzyga in CIDP Administered at Different Infusion Rates

the 12 months prior to baseline visit Respiratory impairment requiring mechanical ventilation Myelopathy or evidence of central nervous system demyelination or significant persisting neurological deficits from stroke, or central nervous system (CNS) trauma Clinical evidence of peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus (SLE) HIV infection, hepatitis, Lyme disease cancer (with the exception of basal cell skin cancer) IgM paraproteinemia (...) ). Patients already receiving IVIG must be on 3- or 4-weekly IVIG treatment schedule with a calculated monthly dosage between 0.8 g/kg and 2.0 g/kg BW ≥ 18 years of age Voluntarily given, fully informed written consent obtained from patient before any study-related procedures are conducted For enrolment into the Second Phase: At each of the last three infusions in the First Phase, administration of panzyga® had to be at the maximum infusion rate of 0.08 mL/kg/min and good tolerated- assessment

2017 Clinical Trials

55. MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study

Biomedicals, LLC Study Details Study Description Go to Brief Summary: This post-market study is intended to assess the performance of the HTLV Blot 2.4 in repository serum/plasma specimens with neurological disorders (n=100) or an HTLV known positive infection (n=50). Condition or disease Intervention/treatment Phase HTLV-I Infections HTLV-II Infections Human T-lymphotropic Virus 1 Human T-lymphotropic Virus 2 HTLV I Associated T Cell Leukemia Lymphoma HTLV I Associated Myelopathies Diagnostic Test: MP (...) Inflammatory Demyelinating Polyneuropathy Dermatomyositis HTLV associated myelopathy-tropical spastic paraparesis (HAM-TSP) Meningitis Mild Cognitive Impairment Multiple Sclerosis (MS) Polymyositis Spastic Paraparesis Sciatica Exclusion Criteria: HTLV Infected: specimens with a known infection or history of HIV, HCV or HBV specimens not meeting specimen labeling collection / handling criteria Neurological Disorders specimens not meeting specimen labeling collection / handling criteria Contacts

2017 Clinical Trials

56. Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. Full Text available with Trip Pro

in the leptomeningeal compartment in 254 people with non-MS neurologic conditions or neurotropic viral infections. Based on their clinical diagnosis, patients were grouped as follows: (1) other-than-MS inflammatory neurologic diseases; (2) noninflammatory neurologic diseases; (3) human T-lymphotropic virus (HTLV)-infected; (4) HIV-infected; (5) healthy volunteers.LME was detected in 56/254 non-MS cases (22%) vs 74/299 (25%) of MS cases. LME was nearly 4-fold more frequent in non-MS inflammatory neurologic (...) conditions (18/51 cases, 35%) than in noninflammatory neurologic conditions (3/38, 8%) and healthy volunteers (5/66, 8%). The highest prevalence of LME was detected in HTLV infection (17/38 cases, 45%), particularly in the setting of HTLV-associated myelopathy (14/25 cases, 56%). LME also frequently occurred in HIV infection (13/61 cases, 21%). Unlike in MS, LME is not associated with lower brain and cortical volumes in non-MS inflammatory neurologic conditions, including HTLV and HIV infection.Despite

2017 Neurology

57. Abnormal Gait and Balance Causes in the Elderly

Administration 4 Abnormal Gait and Balance Causes in the Elderly Abnormal Gait and Balance Causes in the Elderly Aka: Abnormal Gait and Balance Causes in the Elderly II. Causes: Psychiatric Disorders Disorders III. Causes: Cardiovascular Disorders Arrhythmia IV. Causes: Infectious Disorders Induced (HIV-related ) V. Causes: Metabolic Disorders and VI. Causes: Musculoskeletal Disorders VII. Causes: Neurologic Disorders Cerebellar Degeneration Myelopathy Normal-pressure Vestibular disorders VIII. Causes (...) : Miscellaneous Hearing Medications IX. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Abnormal Gait and Balance Causes in the Elderly." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Examination About FPnotebook.com is a rapid access, point-of-care medical reference for primary care and emergency clinicians. Started in 1995

2018 FP Notebook

58. Family Practice Notebook Updates 2016

and Genvoya are first line, one pill daily regimens for therapy naive, non-pregnant HIV patients based therapy with Atripla is no longer first-line therapy as of 2015 (uro, ) Treat suspected STD-related with IM 250 mg and oral 100 bid for 10 days Age over 35 and no concern for STD, treat with or for 10 days Insertive anal intercourse history should prompt 250 IM, then or for 10 days is inadequate for ( resistance) (lung, tb) (e.g. Quantiferon Gold) is a more accurate, reproducible test regardless of than (...) (or ingested) (e.g. lime or lemon) Use , eliminate and if inflamed, (neuro, cv, bleed) In suspected SAH, when is negative, LP is a true positive in 0.4%, and false positive in 4.2% (id, prevent) Highest infection risk is for an HBab negative exposed patient (30% risk if source is positive) For a positive source, HCV transmission is 1.8% and is 0.3% is available for HIV and HBV exposures (pharm, analgesia, ) is reponsible for 30% of prescription related deaths, but accounts for only 2% of the prescriptions

2018 FP Notebook

59. Abnormal Gait and Balance Causes in the Elderly

Administration 4 Abnormal Gait and Balance Causes in the Elderly Abnormal Gait and Balance Causes in the Elderly Aka: Abnormal Gait and Balance Causes in the Elderly II. Causes: Psychiatric Disorders Disorders III. Causes: Cardiovascular Disorders Arrhythmia IV. Causes: Infectious Disorders Induced (HIV-related ) V. Causes: Metabolic Disorders and VI. Causes: Musculoskeletal Disorders VII. Causes: Neurologic Disorders Cerebellar Degeneration Myelopathy Normal-pressure Vestibular disorders VIII. Causes (...) : Miscellaneous Hearing Medications IX. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Abnormal Gait and Balance Causes in the Elderly." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Examination About FPnotebook.com is a rapid access, point-of-care medical reference for primary care and emergency clinicians. Started in 1995

2017 FP Notebook

60. Family Practice Notebook Updates 2016

and Genvoya are first line, one pill daily regimens for therapy naive, non-pregnant HIV patients based therapy with Atripla is no longer first-line therapy as of 2015 (uro, ) Treat suspected STD-related with IM 250 mg and oral 100 bid for 10 days Age over 35 and no concern for STD, treat with or for 10 days Insertive anal intercourse history should prompt 250 IM, then or for 10 days is inadequate for ( resistance) (lung, tb) (e.g. Quantiferon Gold) is a more accurate, reproducible test regardless of than (...) (or ingested) (e.g. lime or lemon) Use , eliminate and if inflamed, (neuro, cv, bleed) In suspected SAH, when is negative, LP is a true positive in 0.4%, and false positive in 4.2% (id, prevent) Highest infection risk is for an HBab negative exposed patient (30% risk if source is positive) For a positive source, HCV transmission is 1.8% and is 0.3% is available for HIV and HBV exposures (pharm, analgesia, ) is reponsible for 30% of prescription related deaths, but accounts for only 2% of the prescriptions

2017 FP Notebook

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>